Over the past three decades, the average number of prescription and non-prescription medications used by pregnant women has increased by more than 60%.1
Furthermore, little is understood of the potential impacts of many medications or combinations of medications on the developing baby because pregnant women are generally excluded from clinical trials.2 On one hand, medications may be essential to treat a mother's ongoing health condition so she can support a healthy pregnancy. On the other hand, those very same medications may present a direct risk to the developing baby. Urine drug testing can help protect mother and baby from complications before they occur.
Pregnancy may significantly change the way drugs are processed by the body, which means a mother's optimal drug regimen or dosing may be different while pregnant.3 In addition, the use of certain medications can result in unfavorable metabolic interactions that pose a risk to the developing baby.4 Risks to the baby further increase if a mother-to-be is combining drugs, whether prescription or non-prescription. For example, the use of multiple anti-epileptic medications, whose indications also include treating psychiatric and pain disorders, is associated with an increased risk of birth defects.5
Overuse, misuse, and abuse of medications, illicit drugs, alcohol, or tobacco during pregnancy significantly increases the chance of immediate health problems for both mom and the developing baby. Furthermore, maternal drug use can have enduring health consequences to the unborn child over his or her lifetime.6
Kashi Urine Drug Testing in OB/GYN may Offer the Information Clinicians Need
- Monitor medication therapy to help support treatment decisions, particularly if controlled substances are required
- Detect medications that may result in potentially harmful drug-to-drug interactions
- Enable health care providers to advocate for, and communicate with, patients about individual treatment plans
- Identify possible illicit drug or medication abuse, misuse or diversion
Make Kashi's testing services part of your treatment planning.
- Mitchell AA et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011; 205(1):51.e1-8.
- Andrade SE et al. Medication Exposure in Pregnancy Risk Evaluation Program. Matern Child Health J. 2012; 16(7):1349-54.
- Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014; 5(April):65.
- Van Gelder MMHJ et al. Teratogenic mechanisms of medical drugs. Hum Reprod Update. 2010; 16(4):378-94.
- Kluger BM and Meador KJ. Teratogenicity of Antiepileptic Medications. Semin Neurol. 2008; 28(3):328-335.
- Minnes S et al. Prenatal tobacco, marijuana, stimulant, and opiate exposure: outcomes and practice implications. Addict Sci Clin Pract. 2011; 6(1):57-70.